KR20170078654A - 코판리십 및 그의 디히드로클로라이드 염의 합성 - Google Patents
코판리십 및 그의 디히드로클로라이드 염의 합성 Download PDFInfo
- Publication number
- KR20170078654A KR20170078654A KR1020177011704A KR20177011704A KR20170078654A KR 20170078654 A KR20170078654 A KR 20170078654A KR 1020177011704 A KR1020177011704 A KR 1020177011704A KR 20177011704 A KR20177011704 A KR 20177011704A KR 20170078654 A KR20170078654 A KR 20170078654A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- optionally
- rti
- solvent
- Prior art date
Links
- ZROYKUBDBPTBSM-UHFFFAOYSA-N COc(c(N)c(cc1)C2=NCCN2)c1OCCCN1CCOCC1 Chemical compound COc(c(N)c(cc1)C2=NCCN2)c1OCCCN1CCOCC1 ZROYKUBDBPTBSM-UHFFFAOYSA-N 0.000 description 2
- PHCNQUJHXJQLQR-UHFFFAOYSA-N COc(c([N+]([O-])=O)c(C=O)cc1)c1O Chemical compound COc(c([N+]([O-])=O)c(C=O)cc1)c1O PHCNQUJHXJQLQR-UHFFFAOYSA-N 0.000 description 1
- MFAGOHPTZMSDPF-UHFFFAOYSA-N COc(c([N+]([O-])=O)c(cc1)C2=NCCN2)c1OCCCN1CCOCC1 Chemical compound COc(c([N+]([O-])=O)c(cc1)C2=NCCN2)c1OCCCN1CCOCC1 MFAGOHPTZMSDPF-UHFFFAOYSA-N 0.000 description 1
- ZYVGMXTZLDVOIW-UHFFFAOYSA-N COc(c1c(cc2)C3=NCCN3C(N)=N1)c2OCCCN1CCOCC1 Chemical compound COc(c1c(cc2)C3=NCCN3C(N)=N1)c2OCCCN1CCOCC1 ZYVGMXTZLDVOIW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192202.1A EP3018131A1 (en) | 2014-11-07 | 2014-11-07 | Synthesis of copanlisib and its dihydrochloride salt |
| EP14192202.1 | 2014-11-07 | ||
| PCT/EP2015/075765 WO2016071426A1 (en) | 2014-11-07 | 2015-11-05 | Synthesis of copanlisib and its dihydrochloride salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170078654A true KR20170078654A (ko) | 2017-07-07 |
| KR102562286B1 KR102562286B1 (ko) | 2023-08-02 |
Family
ID=51866060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177011704A KR102562286B1 (ko) | 2014-11-07 | 2015-11-05 | 코판리십 및 그의 디히드로클로라이드 염의 합성 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US10035803B2 (und) |
| EP (2) | EP3018131A1 (und) |
| JP (1) | JP6691114B2 (und) |
| KR (1) | KR102562286B1 (und) |
| CN (1) | CN107074776B (und) |
| AR (1) | AR102568A1 (und) |
| AU (1) | AU2015341779B2 (und) |
| BR (1) | BR112017009471B1 (und) |
| CA (1) | CA2966796C (und) |
| CL (1) | CL2017001130A1 (und) |
| CO (1) | CO2017004533A2 (und) |
| DK (1) | DK3215507T3 (und) |
| EA (1) | EA031248B1 (und) |
| ES (1) | ES2716730T3 (und) |
| HR (1) | HRP20190527T8 (und) |
| HU (1) | HUE042794T2 (und) |
| IL (1) | IL251586B (und) |
| JO (1) | JO3487B1 (und) |
| LT (1) | LT3215507T (und) |
| MX (1) | MX365111B (und) |
| MY (1) | MY183123A (und) |
| NZ (1) | NZ730843A (und) |
| PE (1) | PE20170951A1 (und) |
| PL (1) | PL3215507T3 (und) |
| PT (1) | PT3215507T (und) |
| RS (1) | RS58494B1 (und) |
| SG (1) | SG11201702999XA (und) |
| SI (1) | SI3215507T1 (und) |
| TR (1) | TR201904346T4 (und) |
| TW (1) | TWI697494B (und) |
| UA (1) | UA118999C2 (und) |
| UY (1) | UY36396A (und) |
| WO (1) | WO2016071426A1 (und) |
| ZA (1) | ZA201703866B (und) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| ES2708350T3 (es) | 2013-04-08 | 2019-04-09 | Bayer Pharma AG | Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas para el tratamiento de linfomas |
| EP3018127A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| CA2978830A1 (en) | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
| CN108884098B (zh) | 2016-03-08 | 2021-09-14 | 拜耳制药股份公司 | 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类 |
| CN109729716B (zh) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
| US11185549B2 (en) | 2017-06-28 | 2021-11-30 | Bayer Consumer Care Ag | Combination of a PI3K-inhibitor with an androgen receptor antagonist |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008070150A1 (en) * | 2006-12-05 | 2008-06-12 | Bayer Schering Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| WO2012136553A1 (en) * | 2011-04-05 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1319674B1 (it) * | 2000-12-01 | 2003-10-23 | Erregierre Spa | Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico. |
| TW565582B (en) * | 2001-04-13 | 2003-12-11 | Kaneka Corp | Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them |
| US7375232B2 (en) * | 2001-08-15 | 2008-05-20 | E.I. Du Pont De Nemours And Company | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests |
| KR101059652B1 (ko) | 2002-09-30 | 2011-08-25 | 바이엘 파마 악티엔게젤샤프트 | 접합 아졸-피리미딘 유도체 |
| WO2009091550A2 (en) * | 2008-01-14 | 2009-07-23 | Bayer Healthcare Llc | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
| MY156209A (en) | 2009-11-04 | 2016-01-29 | Novartis Ag | Heterocyclic sulfonamide derivatives useful mek inhibitors |
-
2014
- 2014-11-07 EP EP14192202.1A patent/EP3018131A1/en not_active Withdrawn
-
2015
- 2015-05-11 UA UAA201705431A patent/UA118999C2/uk unknown
- 2015-11-03 JO JOP/2015/0273A patent/JO3487B1/ar active
- 2015-11-05 MY MYPI2017701571A patent/MY183123A/en unknown
- 2015-11-05 CN CN201580059995.1A patent/CN107074776B/zh active Active
- 2015-11-05 LT LTEP15790141.4T patent/LT3215507T/lt unknown
- 2015-11-05 US US15/524,478 patent/US10035803B2/en active Active
- 2015-11-05 JP JP2017523873A patent/JP6691114B2/ja active Active
- 2015-11-05 SI SI201530660T patent/SI3215507T1/sl unknown
- 2015-11-05 PT PT15790141T patent/PT3215507T/pt unknown
- 2015-11-05 PE PE2017000848A patent/PE20170951A1/es unknown
- 2015-11-05 EP EP15790141.4A patent/EP3215507B1/en active Active
- 2015-11-05 AU AU2015341779A patent/AU2015341779B2/en active Active
- 2015-11-05 TR TR2019/04346T patent/TR201904346T4/tr unknown
- 2015-11-05 HU HUE15790141A patent/HUE042794T2/hu unknown
- 2015-11-05 KR KR1020177011704A patent/KR102562286B1/ko active IP Right Grant
- 2015-11-05 ES ES15790141T patent/ES2716730T3/es active Active
- 2015-11-05 BR BR112017009471-1A patent/BR112017009471B1/pt active IP Right Grant
- 2015-11-05 RS RS20190398A patent/RS58494B1/sr unknown
- 2015-11-05 NZ NZ730843A patent/NZ730843A/en unknown
- 2015-11-05 WO PCT/EP2015/075765 patent/WO2016071426A1/en active Application Filing
- 2015-11-05 SG SG11201702999XA patent/SG11201702999XA/en unknown
- 2015-11-05 DK DK15790141.4T patent/DK3215507T3/en active
- 2015-11-05 EA EA201790982A patent/EA031248B1/ru not_active IP Right Cessation
- 2015-11-05 CA CA2966796A patent/CA2966796C/en active Active
- 2015-11-05 PL PL15790141T patent/PL3215507T3/pl unknown
- 2015-11-05 MX MX2017005891A patent/MX365111B/es active IP Right Grant
- 2015-11-06 UY UY0001036396A patent/UY36396A/es not_active Application Discontinuation
- 2015-11-06 TW TW104136727A patent/TWI697494B/zh active
- 2015-11-06 AR ARP150103617A patent/AR102568A1/es unknown
-
2017
- 2017-04-05 IL IL251586A patent/IL251586B/en active IP Right Grant
- 2017-05-05 CL CL2017001130A patent/CL2017001130A1/es unknown
- 2017-05-05 CO CONC2017/0004533A patent/CO2017004533A2/es unknown
- 2017-06-06 ZA ZA2017/03866A patent/ZA201703866B/en unknown
-
2019
- 2019-03-18 HR HRP20190527TT patent/HRP20190527T8/hr unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008070150A1 (en) * | 2006-12-05 | 2008-06-12 | Bayer Schering Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| WO2012136553A1 (en) * | 2011-04-05 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102562286B1 (ko) | 코판리십 및 그의 디히드로클로라이드 염의 합성 | |
| EP3215493B1 (en) | Synthesis of copanlisib and its dihydrochloride salt | |
| KR20180137496A (ko) | 인다졸의 합성 | |
| TWI716060B (zh) | 用於合成2-羥基喹㗁啉的區域選擇性一步驟方法 | |
| WO2016071382A1 (en) | Synthesis of pi3k inhibitor and salts thereof | |
| CN111606910A (zh) | 一种抗肿瘤药物Sapanisertib的合成工艺 | |
| CN113444023B (zh) | 一种叔丁氧羰基保护的氨类化合物的合成方法及应用 | |
| Zhou et al. | Synthesis and analysis of 1-methyl-4-phenyl-1H-imidazol-2-amine | |
| WO2016071380A1 (en) | Synthesis of pi3k inhibitor and salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |